Evidence map›Paper›PMID 9926917›Full record

ArticleOncogene1999

Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors.

M Khanna, P Park, M Zirvi, W Cao, A Picon, J Day, P Paty, F Barany

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 169 citations in OpenAlex.

  1. Fluorescence-Based Detection ofMethods and protocols · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. RAS testing in metastatic colorectal cancer: advances in Europe.Virchows Archiv : an international journal of pathology · 2016
    Review
  16. Article
  17. Article
  18. Development of a gLCR-based KRAS mutation detection approach and its comparison with other screening methods.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

M KhannaDepartment of Microbiology, Hearst Microbiology Research Center, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA.
P Park
M Zirvi
W Cao
A Picon
J Day
P Paty
F Barany
Hearst (United States) · USMemorial Sloan Kettering Cancer Center · USStrang Cancer Prevention Institute · US

Funding

NEW METHODS FOR CANCER DETECTIONP01CA065930 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARANY, FRANCIS · 1997 to 2007
$14.1M
NCI NIH HHS CA65930-02
6 · The paper itself

Abstract

Point mutations in codons 12, 13, and 61 of the K-ras gene occur early in the development of colorectal cancer and are preserved throughout the course of tumor progression. These mutations can serve as biomarkers for shed or circulating tumor cells and may be useful for diagnosis of early, curable tumors and for staging of advanced cancers. We have developed a multiplex polymerase chain reaction/ligase detection reaction (PCR/LDR) method which identifies all 19 possible single-base mutations in K-ras codons 12, 13, and 61, with a sensitivity of 1 in 500 wild-type sequences. In a blinded study, 144 paraffin-embedded archival colon carcinomas were microdissected and K-ras mutations determined by both dideoxy-sequencing and multiplex PCR/LDR. Results were concordant for 134 samples. The ten discordant samples were re-evaluated using higher sensitivity uniplex PCR/LDR, and the original multiplex PCR/LDR result was confirmed in nine of these ten cases. Multiplex PCR/LDR was able to identify mutations in solid tumors or paraffin-embedded tissues containing a majority of wild-type stromal cells, with or without microdissection. The technique is well suited for large scale studies and for analysis of clinical samples containing a minority population of mutated cells.

Indexed as

Genes, rasPoint MutationColorectal NeoplasmsDNA PrimersHT29 CellsHumansPolymerase Chain ReactionTumor Cells, CulturedDNA Primers

Identifiers

PMID9926917
OpenAlexW1976712578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.